文献速递免疫规划传染病防控与疫情报告

黄病毒疫苗:病毒样颗粒与单轮感染颗粒作为有前景的替代方案

Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
PubMed 文献 · Vaccine · 2021-11-06

黄病毒属包括登革、寨卡、日本脑炎和黄热病毒等人类病原体,现有疫苗可致严重副作用或效果较低。本文讨论重组疫苗中病毒样颗粒(VLP)和单轮感染颗粒(SRIP)的设计生产方法、安全性与有效性证据及商业化挑战。

要点

  • VLP由异源系统产生的病毒结构蛋白自组装而成,结构几乎与天然病毒相同。
  • VLP高度免疫原性,作为其他病毒疫苗已有效使用超过30年。
  • SRIP表达病毒蛋白,可诱导细胞和体液免疫应答,是有前景的候选疫苗。

核心结论

  • VLP和SRIP是应对黄病毒现有疫苗副作用或低有效性问题的有前景的替代疫苗策略。

研究设计与样本

  • 综述,讨论黄病毒VLP和SRIP的设计生产方法、安全性与有效性证据及商业化挑战。

主要发现

  • VLP由异源系统产生的病毒结构蛋白自组装成几乎与天然病毒相同的结构,高度免疫原性。
  • VLP作为其他病毒疫苗已有效使用超过30年。
  • SRIP表达病毒蛋白,诱导细胞和体液免疫应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The genus flavivirus of the Flaviridae family includes several human pathogens, like dengue, Zika, Japanese encephalitis, and yellow fever virus. These viruses continue to be a significant threat to human health. Vaccination remains the most useful approach to reduce the impact of flavivirus fever. However, currently available vaccines can induce severe side effects or have low effectiveness. An alternative is the use of recombinant vaccines, of which virus-like particles (VLP) and single-round infectious particles (SRIP) are of especial interest. VLP consist of the virus structural proteins produced in a heterologous system that self-assemble in a structure almost identical to the native virus. They are highly immunogenic and have been effective vaccines for other viruses for over 30 years. SRIP are promising vaccine candidates, as they induce both cellular and humoral responses, as viral proteins are expressed. Here, the state of the art to produce both types of particles and their use as vaccines against flaviviruses are discussed. We summarize the different approaches used for the design and production of flavivirus VLP and SRIP, the evidence for their safety and efficacy, and the main challenges for their use as commercial vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cuevas-Juárez E, Pando-Robles V, Palomares LA, et al. Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives. Vaccine. 2021. PMID: 34753613. doi:10.1016/j.vaccine.2021.10.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。